£700,000 UK government investment in Randox R&D
£700,000 UK government investment in Randox R&D
A £700,000 UK Research and Innovation investment into manufacturing processes at Randox means patients could benefit from quicker, cheaper and more consistent diagnosis of diseases.
The announcement comes exactly one year after the government launched its modern Industrial Strategy – the long-term plan to boost productivity by backing businesses to create high-quality, well-paid jobs in every corner of the United Kingdom.
The Industrial Strategy Challenge Fund (ISCF) award, administered by UK Research and Innovation (UKRI), will allow Randox Laboratories to further develop its state-of-the-art ‘freeze-drying’ technology which enables the components of vital diagnostic kits to be manufactured, stored and transported more effectively, producing better and speedier diagnoses.
For the first time it also allows this complicated manufacturing process to be carried out in the UK rather than having to be outsourced to countries such as the United States, bringing more jobs and economic growth. These new genomic analysis tools also have the potential to make a major impact in the global fight against antimicrobial resistance by identifying and quickly sharing information about resistant microbial strains.
More in-depth analysis of biomarkers in blood and other bodily fluid levels will allow better, quicker diagnosis of cancers and a range of other diseases, ranging from respiratory infections to sepsis, such as blood poisoning.
The Secretary of State for Northern Ireland said:
“I am delighted to announce a £700,000k UK Government investment in Randox, a multinational life sciences company in County Antrim. This funding will bring significant benefits to Randox’s vital medical diagnostics and help create well-paid manufacturing jobs in Northern Ireland.
“A year-on from the launch of our Modern Industrial Strategy, this investment highlights the great progress we are making to boost productivity by backing leading businesses and creating high-quality jobs in every corner of the United Kingdom.”
John Penrose, Minister of State for Northern Ireland, who visited Randox today to mark the new investment, said:
“Everyone always says the UK needs more high-tec, high-value added manufacturing and the high-skilled, high-waged jobs it brings. But Randox are actually doing it right here in Northern Ireland. This is properly world leading, cutting-edge industry and I’m delighted that today’s money is helping bring the vision to life.”
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented:
“Innovative diagnostic technologies are not only capable of diagnosing disease and ill-health at the earliest possible stage, but they also have a real potential to advance personalised medicine. Our commitment to developing new and exciting breakthroughs in science, technology, engineering and manufacturing is therefore matched only, by our passion to transform the life of the patient. Randox is leading the way in moving from a one-size-fits-all approach towards decisions, practices, and products tailored to the needs of the individual and the Industrial Strategy Challenge Fund award brings us one step closer to realising that aim.”
Funded through UK Research and Innovation, the award forms part of the ISCF Early Diagnosis and Precision Medicine programme, focusing on the use of diagnostic information and genetic analysis to drive more personalised healthcare. Innovate UK, now part of UK Research and Innovation, has supported Randox extensively since 2010, helping grow and scale an innovative diagnostics company who are now distributing their products all over the world.
The announcement comes after the government’s announcement of the Life Sciences Sector Deal that will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy. The deal signals a vote in confidence in UK industry, with global biopharmaceutical company UCB investing around £1 billion in research and development.
For further information please contact Randox PR by emailing randoxpr@randox.com
The Gift of Health: FREE Specialised Test with every Everyman or Everywoman purchased in December
This December, treat your friends and family to the greatest gift of all. The gift of health.
Throughout the month, Randox Health are offering a free Specialised Test, Cough, Cold & Flu, with every Everyman or Everywoman Programme purchased.
Examining up to 150 different indicators of health in your body! The programmes are among the most advanced in the world with our Signature Programme being the most advanced, examining up to 350 different indicators of disease and ill-health. This is due to our advanced technology.
The perfect gift, or perhaps Christmas treat for yourself? These 12-month programmes are guaranteed to give you the most advanced picture available of your current health status.
This month, each programme also comes with a free Cough, Cold & Flu check worth £100.
What is the Cough, Cold and Flu check?
In a world where warnings about antibiotic resistance make daily headlines, Randox Health is helping people take back control.
Antibiotics are used to prevent and treat antibiotic infections. But they don’t work for everything. Taking them when we don’t need them can enable dangerous bacteria that lives inside us to become resistant. That means if you need antibiotics in the future, they may not work. As the NHS says, this puts you and your family at serious risk.
Only bacterial infections can be treated with antibiotics, so finding out what’s behind your infection is essential.
With the Randox Health Cough, Cold and Flu test one swab can detect and identify the cause of 21 respiratory infections in just five hours. With this knowledge, you will find out what’s treatment is going to be appropriate for you.
Take the guesswork out of getting better and book your Cough, Cold and Flu test either as a standalone check or for free with or Everyman or Everywoman Programme.
Specialised tests are available at our clinics in London, Liverpool, Holywood and Crumlin, and also through our innovative mobile health clinic. Gift cards can be purchased from as little as £20.
To find out more about the offer or to purchase the most thoughtful of Christmas presents – a gift card for the ‘gift of health’ – please phone our team on 0800 2545 130. You can also drop them an email. info@randoxhealth.com
Detecting the earliest possible signs of type 2 diabetes
Randox Laboratories is this month driving awareness of diabetes and the need for early and accurate diagnosis to enable patients to take preventive action before the condition worsens.
Diabetes UK have stated that diabetes is the fastest growing health threat of our times and an urgent public health issue. Statistics show that since 1996, the number of people living with diabetes has more than doubled. It has been estimated that there are 1.1 million people living with diabetes in the UK that have yet to be diagnosed, including 84,836 people in Northern Ireland.
According to Diabetes UK around 700 people a day are diagnosed with diabetes, which equates to one person every two minutes. If nothing changes, it is estimated that diabetes will affect one in ten people by 2040. This will raise diabetes prevalence from 415 million to 642 million by 2040. With current treatment taking up almost 9% of the annual NHS budget – roughly £8.8bn a year – the implications for future healthcare budgets are clear if this dangerous trend persists.
The good news however, is that recent research has found that type 2 diabetes is preventable through lifestyle changes. The NHS recently released the UK’s National Diabetes Prevention Programme which is aimed at tackling the increasing growing threat of diabetes.
However, following a warning raised by an Oxford University study, which looked into efforts of this Prevention Programme, it was found that it is unlikely to have much impact because the blood tests used were inaccurate at detecting pre-diabetes – the stage at which diabetes is reversible.
The blood tests used in the National Diabetes Prevention Programme were only effective at detecting diabetes at a stage when damage had already been done.
At Randox, we have developed a number of tests that can help detect the earliest possible signs of diabetes, often before symptoms have even manifested – including a pioneering test for the hormone Adiponectin.
Assessing Adiponectin levels allows doctors to calculate a patient’s levels of visceral fat – a dangerous, internal fat stored around organs. This deep fat, which is not visible to the naked eye, is linked to health problems including Type-2 diabetes.
Low levels of adiponectin equate to high levels of visceral fat which can be combated by improving your diet, exercise habits and even stress levels. Given that 70% of Type-2 diabetes can be prevented by lifestyle changes, there is strong correlation that by detecting low levels of Adiponectin and taking corrective and preventive action, it could result in a decrease in the numbers of people who develop the life-altering condition.
In addition to a test for the Adiponectin biomarker, Randox Biosciences have created a Metabolic Syndrome Array that measures 12 markers associated with metabolic syndrome and cardiovascular disease. Metabolic Syndrome is a is a group of cardiovascular risk factors that affects over 20% of adults and results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.
Ultimately, we would like to see all medical professionals who are at the forefront of patient care armed with the most accurate diagnostic tools available. Updating traditional practice may not be easy but we believe it is imperative to do so, if we are to effectively challenge this global epidemic.
Randox remains focused on providing early diagnoses and preventing illnesses by providing innovative diagnostics tests that will continue to revolutionise the healthcare landscape.
For further information, please contact Randox PR by emailing randoxpr@randox.com or phoning 028 9442 2413.
Randox Teoranta set to host Science, Engineering and Manufacturing Career Open Day on Christmas Eve
Do you have a flair for science? Are you an electronic, mechanical or software engineering expert? Or, perhaps, you are a mastermind of manufacturing know-how. There are world-leading careers on offer for world-leading candidates at Randox Teoranta in Dungloe this December.
That’s the message that global diagnostics firm Randox Teoranta wants to send to students, graduates and experienced professionals alike as it opens its doors to the public once again on Monday 24th December 2018.
Held from 9am to 12noon, the morning is an opportunity for those interested in science, engineering, software development and manufacturing roles in Donegal to have a tour of the state-of-the-art facility and chat with Randox Teoranta staff members about the careers on offer.
Randox Teoranta is particularly passionate about attracting back those who have left Ireland to find careers further afield due to lack of opportunities in their particular vocations. Dream careers in science, engineering and manufacturing are available on the doorstep in Dungloe.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta, commented;
“At Randox Teoranta, we’re constantly pushing the boundaries of healthcare and diagnostic capabilities, allowing us to offer world-class career opportunities in the heart of Donegal.
“Our scientists are working on a range of research projects which will lead to quicker diagnoses of conditions such as stroke, gastrointestinal disorders and chronic kidney disease. In 2016, our scientists even developed a pioneering new test to determine a patient’s risk of developing Alzheimer’s disease.
“There are also opportunities for software developers, electronic & embedded systems engineers, validation and mechanical engineers as our technology continues to advance to accommode our scientific breakthroughs.
“Our manufacturing department also boasts a number of competitive roles which are essential to Randox Teoranta’s continuation as a world leader in healthcare diagnostics and associated technology.
“There are fantastic career opportunities here in one of the most beautiful parts of the world – and the quality of life is second-to-none.”
There are a wide variety of career opportunities available at Randox Teoranta. From placement opportunities for college and university students to graduate roles in a variety of fields, young scientists and engineers have the opportunity to get their ‘big break’ on the career ladder with a globally-recognised company.
There are also opportunities for experienced and driven individuals looking for a smart career move. Randox Teoranta offer competitive salaries, career progression, personal development and the opportunity to work in a cutting-edge company paving the way in ground-breaking global health diagnostics.
Healthcare shouldn’t be one-size-fits-all. Neither should your career.
Randox Teoranta’s Open Morning will take place on Monday 24th December 2018 from 9:00 until 12:00 at Randox Teoranta, Meenmore, Dungloe, Co. Donegal.
Students, graduates and experienced professionals are welcome to visit along with their family and friends. Potential candidates are welcome to bring their CV on the day or email it to recruitment@randoxteoranta.com.
Booking is not required, however, more information, including directions, can be found by searching Randox at www.eventbrite.ie.
More information about the open day can also be found by contacting +353 7495 22600 or emailing RandoxPR@randox.com.
Randox Biosciences and Familial Hypercholesterolemia (FH)
Familial Hypercholesterolemia (FH) is a genetic disorder where the child is born with extremely high cholesterol levels. FH can trace back through several generations. Cholesterol is vital for the normal function of the human body therefore, it is important to ensure the cholesterol levels don’t get too high because it can result in early onset cardiovascular disease. 1
The FH Foundation states an interesting fact that 1 in 250 people worldwide have FH and over 90% of these people have not been properly diagnosed 2. Majority of these people won’t know they have FH disease until they have a heart attack!
However, there are no clear symptoms if someone has FH until it is too late and the damage has been done. The warning signs include the following:1
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Gray-white cholesterol deposits around the corneas
A study in 2008 by the British Heart Foundation found that people with FH who are diagnosed and treated before they develop heart disease live as long people who don’t have FH 4. This theory emphasis the importance of getting early diagnosis to prevent long-term problems. Treatment to prevent cardiovascular disease involves taking medication prescribed by the doctor and making lifestyle changes including; modifying diet, increasing exercise, quit smoking, decrease drinking alcohol and ensure the patient gets regular sleep.
Randox offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time allowing results to be reported within days compared to NHS waiting lists which can be substantially longer. The two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes. The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing with NGS. The genetic analysis for FH mutations allows for more accurate diagnosis compared to lipid profiling.
Randox can help using the award-winning Biochip Analyser to achieve early and appropriate treatment for those with FH resulting those to adopt a healthier lifestyle and taking cholesterol-lowering medication, risk of heart disease to live a longer and healthy life!
Familial Hypercholesterolemia (FH) Arrays I & II:
- LDLR – 38 mutations
- APOB – 1 mutation
- PCSK9 – 1 mutation
To find out more about the products that we offer email us info@randoxbiosciences.com
Reference:
https://www.healthline.com/health/familial-hypercholesterolemia#symptoms
The world’s most extensive Drugs of Abuse Test Menu
Randox Toxicology offers the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays for current and novel drugs trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
| DoA II | ||
| Buprenorphine | Ketamine | Oxycodone I |
| Creatinine | LSD | Oxycodone II |
| Fentanyl | MDMA | Propoxyphene |
| Generic Opioids | Methaqualone | – |
The Evidence Series of immunoassay analysers are powered by Biochip Array Technology and combine the latest technological advances for drug residue detection using immunoassay principles. The Drugs of Abuse II panel is available for both the Evidence and the Evidence Investigator analysers. The Evidence has a throughput of 90 samples per hour, testing up to 44 tests per sample. The Evidence is a fully automated batch immunoanalyser, allowing for 3960 tests per hour, while the Evidence Investigator is a semi-automated, bench top analyser with testing capabilities of 2376 tests in 70 minutes.
To find out more about our Biochip Array Technology and our Evidence Series analysers, visit www.randoxtoxicology.com, or email us at info@randoxtoxicology.com
Tackling Worldwide Drugs of Abuse
Throughout November, we’ve been highlighting how the Randox clinical teams – Randox Rx series, Randox Reagents and Randox QC – are aiding the fight against drugs of abuse.
Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
The abuse of drugs is one of the most pressing issues in the United States of America. Drug abuse not only affects the individual, but also can have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.
- Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.
- Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.
- Substance abuse and addiction also affects other areas of life and can cause broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.
- Drug abuse and addiction changes the chemistry of your brain. The longer you use your drug of choice, the more damage is caused and it becomes more difficult to return to ‘normal’ during drug rehabilitation.
- In 2013, 22.7 million Americans needed treatment for a substance use disorder – almost 9% of the population over the age of 12. Only about 2.5 million received treatment as a specialist facility with 20% of admissions for opiate addication treatment and 17% for the treatment of marijuana abuse.
To find out more about how Randox is helping in the fight against Drugs of Abuse, please visit https://www.randox.com/drugs-of-abuse/ or for more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.
We Are Randox | Match Report from FinTrU Ulster GAA Inter-Firms Junior Men’s Competition
On Saturday 17th November 2018, hot on the heels of the Randox GAA Ladies team’s glorious competition début, our Men’s team took to the field at the Tyrone GAA Centre of Excellence, to compete in the Junior Men’s category of the FinTrU Ulster GAA Football Inter-Firms competition.
With our Ladies team having successfully reached the Semi-Finals of the competition the week prior, the pressure was on!
The two Randox Men’s teams were pooled in separate groups with strong opposition in both. Randox Team One faced a tough task with FinTru, Citi and South West College, whilst the second Randox Team were pitted against the GAA Store, Premier Electric and Belfast Lawyers.
Our Randox teams battled hard during this group stage and thanks to a creative team effort as well as some fantastic individual performances, they both made it to the knockout stages of the competition and into the quarter finals. Unfortunately though, the effort put in to make it out of the group stages had claimed a few key players to injury, which left the remaining men with a near impossible task ahead of them in the next stage of the competition
Team One was drawn against FinTru and Team Two against Belfast Lawyers. Regrettably, on the day both teams came out on the wrong side of the results in very competitive games against very experienced and seasoned teams.
John James Fallon, Randox Electrical Engineer and GAA Bainisteoir / Coach, commented;
“As newly-formed teams, who prior to the Inter-Firms competition had never played together before, both the men and ladies should be extremely proud. Fielding players who ranged from experienced to novice, and with only 5 weeks training, to have reached the quarter-finals and semi-finals of our respective categories has been exceptional.
“On behalf of the organising committee I would like to say thank you to Randox and Dr FitzGerald for their assistance in getting the team started, and to St James GAC Aldergrove for the use of their facilities and equipment over the course of the training sessions, as without their help this would not have been possible. Finally, a huge thank you has to go to the participants themselves, as without you there is no Randox GAA club. I’m looking forward to our next season together already.
“This is just the beginning.”
On behalf of everyone at Randox we would like to wish both our Ladies GAA Team and our two Men’s GAA teams a massive congratulations on their impressive performances at the FinTrU Ulster GAA Football Inter-Firms competition.
Their commitment, perseverance and teamwork has been truly inspiring and we are very proud of how they came together to form three very capable and motivated GAA teams. Well done!
For further information on our Randox GAA teams, please email johnjames.fallon@randox.com
Significant drop in veterinary antibiotics sales across Europe
Randox Food Diagnostics recently reported that the European Parliament has banned the use of antibiotics that are important for human medicine use on animals, and is prohibiting any antimicrobials in livestock without a vet prescription. The new legislation, that is to become law by 2022, states that antimicrobials cannot be used to improve performance or compensate for poor animal conditions.
The European Medicines Agency (EMA) have now documented a significant drop in overall veterinary antibiotic sales across Europe. The EMA recognise that the reduction highlights the efforts made by the European Union (EU) and various stakeholders, promoting prudent use of antibiotics in the animal sector and its positive impact. The reduction of antibiotic use in food-producing animals is a key pillar to the EUs One Health Action Plan against Antimicrobial Resistance (AMR), according to a report conducted by the University of Minnesota.
30 countries in total submitted data between 2011 and 2016. German antibiotic sales dropped by 58%. However, whilst the majority of countries saw a drop in sales, six countries reported an increase of more than 5%. Germany’s implementation of an antibiotic minimising programme has helped the country to minimise antibiotic use, by requiring farmers raising cattle, pigs, chickens, or turkeys to report the frequency of antibiotic treatment on their farm every 6 months. If animal treatment frequency is above the median of all farms, operators must evaluate their usage with a veterinarian.
This major step forward in public health has a direct impact on the environment and food. Randox Food Diagnostics recognise the importance of improving the global food safety chain, and continue to transform the landscape by developing high quality revolutionary screening products. Our reliable and economic testing methods enable the user to detect multiple drug and toxin residues from a single sample, including antimicrobials, growth promoting compounds, synthetic steroids, anthelmintics and coccidiostats. With an expanding range of 37 ELISAs, 21 multiplex screening arrays and 20 enzymatic/colourmetric reagents, our trusted solutions ensure that better science means safer food.
For any questions, email us directly at: info@randoxfooddiagnostics.com
Reporting, Expert Witness and Medical Review Services from RTS
RTS Reporting Services
At Randox Testing Services we provide a number of reporting options to our customers, including expert witness reports and medical reviews to add clarity and expert examination to results.
Expert Witness Services
An Expert Witness Report is an interpretation of the results of a drug or alcohol test. It provides a detailed explanation of whether or not substances tested for were detected as well as information regarding chain of custody compliance and testing procedures.
As trusted industry experts Randox Testing Services staff are trained to act as Expert Witnesses in legal cases involving drug and alcohol testing. Our experienced team of Reporting Scientists have undergone extensive Expert Witness training to provide professional witness statements or fully written reports for use as evidence in a court of law or industrial tribunals.
Where required a Senior Toxicologist from Randox Testing Services can attend legal proceedings in person to provide expert witness testimony.
Medical Review Services
Our medical review service offers independent and expert examination of positive results under medical confidentiality.
A positive result from a drug and alcohol analysis is a cause for concern. However, there are some cases when there is a legitimate medical reason for the result. Our medical review service allows for the independent and confidential review of the result to determine the cause of a positive result, for example, if an employee is taking prescription medication.
The Medical Review Officer (MRO) assesses a positive result in the light of the donor’s medical background to determine if there is a legitimate medical reason for the result. The MRO helps protect both the rights of the employee being tested and the employer requiring the testing.
Randox Testing Services
At Randox Testing Services we offer customers access to our expertise through providing various reporting options to customers. These reporting services can be utilised in cases where extra clarity or examination is needed to investigate the outcome of a drugs test. These reports are utilised by workplaces as well as those operating within the medico-legal sector.
For more information on our training, education and reporting services, click here.
If you would like to find out more about our drug and alcohol testing programs, contact us today to speak to one of our experience business development executives.
Web: www.randoxtestingservices.com
Email: testingservices@randox.com
Phone: +44 (0) 28 9445 1011
